SAFETY UPDATE: Drug resistance emerging during therapy with dolutegravir and other integrase inhibitors

November, 2015 –At least three B.C. patients have developed new integrase resistance mutations affecting dolutegravir and/or raltegravir and elvitegravir which emerged during treatment with dolutegravir 50 mg daily plus abacavir-lamivudine. Two of the three patients also developed new resistance to lamivudine and abacavir. One patient was treatment naïve and two were treatment experienced. None had previously documented drug resistance. Two of these patients achieved virologic suppression followed by rebound, while one never achieved a viral load <40 c/mL. Drug resistance emerged within 8-12 months after starting the dolutegravir-based regimen. Incomplete medication adherence appeared to be a contributing factor.

For more information: Click here to download the BC-CfE Safety Alert (PDF)

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below